Clinical Trial

Clinical and Radiographic Success of MTA vs Biodentine

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated December 23, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-04-27; most recent amendment 2025-12-22.
Status change: Not Yet Recruiting → Recruiting 2021-11-12
Trial Details
NCT Number NCT04863222
Lead Sponsor Geisinger Clinic
Conditions Indirect Pulp Cap, Pulpotomy
Enrollment 646 participants
Start Date 2021-11-12
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-23